{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:30:35Z","timestamp":1792567835437,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The intra-abdominal cavity, surrounded by adipocytes, is the main metastatic site of epithelial ovarian, fallopian tube, and peritoneal cancer. Epidemiological and molecular studies have demonstrated a link between adipose tissue and ovarian cancer. However, the clinical significance of fatty tissue has not been elucidated. Thus, we investigated the clinical significance of body composition in patients with epithelial ovarian, fallopian tube, and peritoneal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fat and skeletal muscle areas were measured using software based on pretreatment computed tomography scans at the third lumbar vertebra. Fat-to-muscle ratios were calculated using the total (visceral and subcutaneous) fat area or visceral fat area. High fat-to-muscle ratios were defined by values greater than the mean. Sarcopenia was defined as a skeletal muscle index &lt; 38.7 cm\n                      <jats:sup>2<\/jats:sup>\n                      \/m\n                      <jats:sup>2<\/jats:sup>\n                      . The clinicopathological parameters and survival of 153 patients were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High visceral fat-to-muscle ratios and sarcopenia at the time of diagnosis were observed in 43.8% and 33.3% of the patients, respectively. Multivariate analysis showed that high visceral fat-to-muscle ratio (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.014), advanced Federation of Gynecology and Obstetrics stage (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008), and chemoresistance (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.027) were independent factors for worse overall survival. Patients with high visceral fat-to-muscle ratios were older, had higher body mass indexes, and were more likely to have diabetes\/hypertension, serous cancer subtypes, and implementation of neoadjuvant chemotherapy than those with low visceral fat-to-muscle ratios. The platelet count was significantly higher in the high visceral fat-to-muscle ratio group than in the low visceral fat-to-muscle ratio group (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pretreatment visceral fat area could be an independent predictive factor of overall survival in patients with epithelial ovarian, fallopian tube, and peritoneal cancer and may be significantly associated with thrombocytosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-023-01098-1","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T03:02:48Z","timestamp":1674270168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["High visceral fat-to-muscle ratio is an independent factor that predicts worse overall survival in patients with primary epithelial ovarian, fallopian tube, and peritoneal cancer"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-0749","authenticated-orcid":false,"given":"Sooji","family":"Ham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5568-7984","authenticated-orcid":false,"given":"Jin Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8479-6445","authenticated-orcid":false,"given":"Soo Gui","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-1059","authenticated-orcid":false,"given":"Eun-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"publisher","unstructured":"Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry. Obstet Gynecol Sci. 2021. https:\/\/doi.org\/10.5468\/ogs.21116.","DOI":"10.5468\/ogs.21116"},{"key":"1098_CR2","doi-asserted-by":"publisher","unstructured":"Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092246.","DOI":"10.1146\/annurev.pathol.4.110807.092246"},{"key":"1098_CR3","doi-asserted-by":"publisher","unstructured":"Dahm-K\u00e4hler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival-A population-based cohort study. Gynecol Oncol. 2016. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.025.","DOI":"10.1016\/j.ygyno.2016.05.025"},{"key":"1098_CR4","doi-asserted-by":"publisher","unstructured":"Quail DF, Dannenberg AJ. The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol. 2019. https:\/\/doi.org\/10.1038\/s41574-018-0126-x.","DOI":"10.1038\/s41574-018-0126-x"},{"key":"1098_CR5","doi-asserted-by":"publisher","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011. https:\/\/doi.org\/10.1038\/nm.2492.","DOI":"10.1038\/nm.2492"},{"key":"1098_CR6","doi-asserted-by":"publisher","unstructured":"M\u00fcller M, Lagerpusch M, Enderle J, Schautz B, Heller M, Bosy-Westphal A. Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev. 2012. https:\/\/doi.org\/10.1111\/j.1467-789X.2012.01033.x.","DOI":"10.1111\/j.1467-789X.2012.01033.x"},{"key":"1098_CR7","doi-asserted-by":"publisher","unstructured":"Kim SI, Kim TM, Lee M, Kim HS, Chung HH, Cho JY, et al. Impact of CT-determined sarcopenia and body composition on survival outcome in patients with advanced-stage high-grade serous ovarian carcinoma. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12030559.","DOI":"10.3390\/cancers12030559"},{"key":"1098_CR8","doi-asserted-by":"publisher","unstructured":"Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.003.","DOI":"10.1016\/j.ygyno.2020.01.003"},{"key":"1098_CR9","doi-asserted-by":"publisher","unstructured":"Ubachs J, Ziemons J, Minis-Rutten IJ, Kruitwagen RF, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019. https:\/\/doi.org\/10.1002\/jcsm.12468.","DOI":"10.1002\/jcsm.12468"},{"key":"1098_CR10","doi-asserted-by":"publisher","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer\u2014viewpoint of the IARC Working Group. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/NEJMsr1606602.","DOI":"10.1056\/NEJMsr1606602"},{"key":"1098_CR11","doi-asserted-by":"publisher","unstructured":"Heus C, Smorenburg A, Stoker J, Rutten M, Amant F, van Lonkhuijzen L. Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study. Gynecol Oncol. 2021. https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.015.","DOI":"10.1016\/j.ygyno.2020.10.015"},{"key":"1098_CR12","doi-asserted-by":"publisher","unstructured":"Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016. https:\/\/doi.org\/10.1002\/jcsm.12107.","DOI":"10.1002\/jcsm.12107"},{"key":"1098_CR13","doi-asserted-by":"publisher","unstructured":"Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, et al. Perirenal adiposity is associated with lower progression-free survival from ovarian cancer. Int J Gynecol Cancer. 2018. https:\/\/doi.org\/10.1097\/IGC.0000000000001165.","DOI":"10.1097\/IGC.0000000000001165"},{"key":"1098_CR14","doi-asserted-by":"publisher","unstructured":"Harada K, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, Izumi D, et al. Low visceral fat content is associated with poor prognosis in a database of 507 upper gastrointestinal cancers. Ann Surg Oncol. 2015. https:\/\/doi.org\/10.1245\/s10434-015-4432-4.","DOI":"10.1245\/s10434-015-4432-4"},{"key":"1098_CR15","doi-asserted-by":"publisher","unstructured":"Basile D, Bartoletti M, Polano M, Bortot L, Gerratana L, Di Nardo P, et al. Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. Clin Nutr. 2021. https:\/\/doi.org\/10.1016\/j.clnu.2020.05.019.","DOI":"10.1016\/j.clnu.2020.05.019"},{"key":"1098_CR16","doi-asserted-by":"publisher","unstructured":"Bian X, Dai H, Feng J, Ji H, Fang Y, Jiang N, et al. Prognostic values of abdominal body compositions on survival in advanced pancreatic cancer. Medicine. 2018. https:\/\/doi.org\/10.1097\/MD.0000000000010988.","DOI":"10.1097\/MD.0000000000010988"},{"key":"1098_CR17","doi-asserted-by":"publisher","unstructured":"Chen HL, Shih CT, Lee YC, Tseng HC, Chou YH. Patients with cervical cancer without visceral obesity had better treatment outcomes. Ther Radiol Oncol. 2020. https:\/\/doi.org\/10.21037\/tro-20-22.","DOI":"10.21037\/tro-20-22"},{"key":"1098_CR18","doi-asserted-by":"publisher","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010. https:\/\/doi.org\/10.2353\/ajpath.2010.100105.","DOI":"10.2353\/ajpath.2010.100105"},{"key":"1098_CR19","doi-asserted-by":"publisher","unstructured":"Dai L, Song K, Di W. Adipocytes: active facilitators in epithelial ovarian cancer progression? J Ovarian Res. 2020. https:\/\/doi.org\/10.1186\/s13048-020-00718-4.","DOI":"10.1186\/s13048-020-00718-4"},{"key":"1098_CR20","doi-asserted-by":"publisher","unstructured":"Chen C, Chang YC, Lan MS, Breslin M. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK\/ERK1\/2 and PI3K\/Akt signaling pathways. Int J Oncol. 2013. https:\/\/doi.org\/10.3892\/ijo.2013.1789.","DOI":"10.3892\/ijo.2013.1789"},{"key":"1098_CR21","doi-asserted-by":"publisher","unstructured":"Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012. https:\/\/doi.org\/10.1016\/j.cyto.2012.04.020.","DOI":"10.1016\/j.cyto.2012.04.020"},{"key":"1098_CR22","doi-asserted-by":"publisher","unstructured":"Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, et al. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0081859.","DOI":"10.1371\/journal.pone.0081859"},{"key":"1098_CR23","doi-asserted-by":"publisher","unstructured":"Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 2014. https:\/\/doi.org\/10.1074\/jbc.M114.558288.","DOI":"10.1074\/jbc.M114.558288"},{"key":"1098_CR24","doi-asserted-by":"publisher","unstructured":"Park SE, Choi JH, Park JY, Kim BJ, Kim JG, Kim JW, et al. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-74765-8.","DOI":"10.1038\/s41598-020-74765-8"},{"key":"1098_CR25","doi-asserted-by":"publisher","unstructured":"Villase\u00f1or A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012. https:\/\/doi.org\/10.1007\/s11764-012-0234-x.","DOI":"10.1007\/s11764-012-0234-x"},{"key":"1098_CR26","doi-asserted-by":"publisher","unstructured":"Ataseven B, Luengo TG, du Bois A, Waltering KU, Traut A, Heitz F, et al. Skeletal muscle attenuation (sarcopenia) predicts reduced overall survival in patients with advanced epithelial ovarian cancer undergoing primary debulking surgery. Ann Surg Oncol. 2018. https:\/\/doi.org\/10.1245\/s10434-018-6683-3.","DOI":"10.1245\/s10434-018-6683-3"},{"key":"1098_CR27","doi-asserted-by":"publisher","unstructured":"Aust S, Knogler T, Pils D, Obermayr E, Reinthaller A, Zahn L, et al. Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS One. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0140403.","DOI":"10.1371\/journal.pone.0140403"},{"key":"1098_CR28","doi-asserted-by":"publisher","unstructured":"Conrad LB, Awdeh H, Acosta-Torres S, Conrad SA, Bailey AA, Miller DS, et al. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. J Surg Oncol. 2018. https:\/\/doi.org\/10.1002\/jso.24990.","DOI":"10.1002\/jso.24990"},{"key":"1098_CR29","doi-asserted-by":"publisher","unstructured":"Kumar A, Moynagh MR, Multinu F, Cliby WA, McGree ME, Weaver AL, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 2016. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.027.","DOI":"10.1016\/j.ygyno.2016.05.027"},{"key":"1098_CR30","doi-asserted-by":"publisher","unstructured":"Nakayama N, Nakayama K, Nakamura K, Razia S, Kyo S. Sarcopenic factors may have no impact on outcomes in ovarian cancer patients. Diagnostics. 2019. https:\/\/doi.org\/10.3390\/diagnostics9040206.","DOI":"10.3390\/diagnostics9040206"},{"key":"1098_CR31","doi-asserted-by":"publisher","unstructured":"Rutten I, Ubachs J, Kruitwagen R, van Dijk D, Beets-Tan R, Massuger L, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur J Surg Oncol. 2017. https:\/\/doi.org\/10.1016\/j.ejso.2016.12.016.","DOI":"10.1016\/j.ejso.2016.12.016"},{"key":"1098_CR32","doi-asserted-by":"publisher","unstructured":"Torres ML, Hartmann LC, Cliby WA, Kalli KR, Young PM, Weaver AL, et al. Nutritional status, CT body composition measures and survival in ovarian cancer. Gynecol Oncol. 2013. https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.003.","DOI":"10.1016\/j.ygyno.2013.03.003"},{"key":"1098_CR33","doi-asserted-by":"publisher","unstructured":"Bronger H, Hederich P, Hapfelmeier A, Metz S, No\u00ebl PB, Kiechle M, et al. Sarcopenia in advanced serous ovarian cancer. Int J Gynecol Cancer. 2017. https:\/\/doi.org\/10.1097\/IGC.0000000000000867.","DOI":"10.1097\/IGC.0000000000000867"},{"key":"1098_CR34","doi-asserted-by":"publisher","unstructured":"Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012. https:\/\/doi.org\/10.1056\/NEJMoa1110352.","DOI":"10.1056\/NEJMoa1110352"},{"key":"1098_CR35","doi-asserted-by":"publisher","unstructured":"Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G, et al. Platelet counts and platelet activation markers in obese subjects. Mediators of inflamm. 2008. https:\/\/doi.org\/10.1155\/2008\/834153.","DOI":"10.1155\/2008\/834153"},{"key":"1098_CR36","doi-asserted-by":"publisher","unstructured":"Raoux L, Moszkowicz D, Vychnevskaia K, Poghosyan T, Beauchet A, Clauser S, et al. Effect of bariatric surgery-induced weight loss on platelet count and mean platelet volume: a 12-month follow-up study. Obes Surg. 2017. https:\/\/doi.org\/10.1007\/s11695-016-2292-z.","DOI":"10.1007\/s11695-016-2292-z"},{"key":"1098_CR37","doi-asserted-by":"publisher","unstructured":"Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab. 2007. https:\/\/doi.org\/10.1152\/ajpendo.00127.2007.","DOI":"10.1152\/ajpendo.00127.2007"},{"key":"1098_CR38","doi-asserted-by":"publisher","unstructured":"Aubrey J, Esfandiari N, Baracos V, Buteau F, Frenette J, Putman C, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 2014. https:\/\/doi.org\/10.1111\/apha.12224.","DOI":"10.1111\/apha.12224"},{"key":"1098_CR39","doi-asserted-by":"publisher","unstructured":"Klabunde C, Legler J, Warren J, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007. https:\/\/doi.org\/10.1016\/j.annepidem.2007.03.011.","DOI":"10.1016\/j.annepidem.2007.03.011"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-023-01098-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-023-01098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T03:04:53Z","timestamp":1674270293000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-023-01098-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1186\/s13048-023-01098-1","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Institutional Review Board of Chung-Ang University Hospital (\n                      \n                      ; approval number: 2104-002-19360; date: April 29, 2021). No written informed consent of the participants was needed because this was a retrospective chart review of existing medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}